Loading...
The glucagon-like peptide-1 (GLP-1)–receptor agonist drugs, developed to treat patients with diabetes, also deliver many additional benefits. In a very large study (7 million person-years of observation), using U.S. Department of Veterans Affairs databases, researchers quantified benefits and risks associated with GLP-1 agonists.
More than 200,000 patients with diabetes who initiated GLP-1 agonists between October 2017 and December 2023 were compared with 535,000 similar patients who initiated sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sodium-glucose cotransporter-2 (SGLT-2) inhibitors in that period. A 1.2 million–member “usual-care” group, who had initiated non–GLP-1 drugs prior to October 2017 and continued such use thro…